MicroRNAs and Colon and Rectal Cancer: Differential Expression by Tumor Location and Subtype

Overview

Journal Genes Chromosomes Cancer

Specialties Molecular Biology
Oncology

Date 2011 Jan 8

PMID 21213373

Citations 72

Authors

Martha L Slattery

Erica Wolff

Michael D Hoffman

Daniel F Pellatt

Brett Milash

Roger K Wolff

Affiliations

Soon will be listed here.

Abstract

MicroRNAs are thought to have an impact on cell proliferation, apoptosis, stress responses, maintenance of stem cell potency, and metabolism and are, therefore, important in the carcinogenic process. In this study, we examined 40 colon tumors, 30 rectal tumors, and 30 normal tissue samples (10 proximal colon, 10 distal colon, and 10 rectal paired with cancer cases) to examine miRNA expression profiles in colon and rectal tumors. MiRNA expression levels were adjusted for multiple comparisons; tumor tissue was compared with noncancerous tissue from the same site. A comparison of normal tissue showed 287 unique miRNAs that were significantly differentially expressed at the 1.5-fold level and 73 with over a two-fold difference in expression between colon and rectal tissue. Examination of miRNAs that were significantly differentially expressed at the 1.5-fold level by tumor phenotype showed 143 unique miRNAs differentially expression for microsatellite instability positive (MSI+) colon tumors; 129 unique miRNAs differentially expressed for CpG Island Methylator Phenotype positive (CIMP+) colon tumors; 135 miRNAs were differentially expressed for KRAS2-mutated colon tumors, and 139 miRNAs were differentially expressed for TP53-mutated colon tumors. Similar numbers of differentially expressed miRNAs were observed for rectal tumors, although the miRNAs differentially expressed differed. There were 129 unique miRNAs for CIMP+, 143 unique miRNAs for KRAS2-mutated, and 136 unique miRNAs for TP53-mutated rectal tumors. These results suggest the importance of miRNAs in colorectal cancer and the need for studies that can confirm these results and provide insight into the diet, lifestyle, and genetic factors that influence miRNA expression.

Citing Articles

Diagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer.

Gattuso G, Longo F, Spoto G, Ricci D, Lavoro A, Candido S Int J Mol Sci. 2025; 26(3).

PMID: 39940987 PMC: 11818852. DOI: 10.3390/ijms26031219.

Evaluation of the Plasma Expression Levels of miR-21 and miR-145 as Potential Non-Invasive Biomarkers for Early Detection of Colorectal Cancer.

Rattan Negi R, Rana S, Gupta V, Gupta R, Dhawan D Asian Pac J Cancer Prev. 2024; 25(8):2797-2804.

PMID: 39205577 PMC: 11495435. DOI: 10.31557/APJCP.2024.25.8.2797.

Restricting Colorectal Cancer Cell Metabolism with Metformin: An Integrated Transcriptomics Study.

Orang A, Marri S, McKinnon R, Petersen J, Michael M Cancers (Basel). 2024; 16(11).

PMID: 38893174 PMC: 11171104. DOI: 10.3390/cancers16112055.

Discovery of Novel miRNAs in Colorectal Cancer: Potential Biological Roles and Clinical Utility.

Minutentag I, Seneda A, Barros-Filhos M, de Carvalho M, Souza V, Hasimoto C Noncoding RNA. 2023; 9(6).

PMID: 37987361 PMC: 10660700. DOI: 10.3390/ncrna9060065.

Comprehensive analysis of alternative splicing signatures in pancreatic head cancer.

Zhou L, Yang Y, Ma J, Liu M, Liu R, Ma X IET Syst Biol. 2022; 17(1):14-26.

PMID: 36479597 PMC: 9931058. DOI: 10.1049/syb2.12056.

References

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

Grady W, Parkin R, Mitchell P, Lee J, Kim Y, Tsuchiya K . Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene. 2008; 27(27):3880-8. DOI: 10.1038/onc.2008.10. View

He X, He L, Hannon G . The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 2007; 67(23):11099-101. DOI: 10.1158/0008-5472.CAN-07-2672. View

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

Hui A, Shi W, Boutros P, Miller N, Pintilie M, Fyles T . Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 2009; 89(5):597-606. DOI: 10.1038/labinvest.2009.12. View

Slattery M, Edwards S, Curtin K, Ma K, Edwards R, Holubkov R . Physical activity and colorectal cancer. Am J Epidemiol. 2003; 158(3):214-24. DOI: 10.1093/aje/kwg134. View

Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C, Fritschi L . The MTHFR C677T and DeltaDNMT3B C-149T polymorphisms confer different risks for right- and left-sided colorectal cancer. Int J Cancer. 2009; 125(1):84-90. DOI: 10.1002/ijc.24324. View

Lanza G, Ferracin M, Gafa R, Veronese A, Spizzo R, Pichiorri F . mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer. 2007; 6:54. PMC: 2048978. DOI: 10.1186/1476-4598-6-54. View

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

10.

Slattery M, Herrick J, Lundgreen A, Wolff R . Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2010; 20(1):57-69. PMC: 3061458. DOI: 10.1158/1055-9965.EPI-10-0843. View

11.

Slattery M, Wolff R, Curtin K, Fitzpatrick F, Herrick J, Potter J . Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res. 2008; 660(1-2):12-21. PMC: 2907671. DOI: 10.1016/j.mrfmmm.2008.10.001. View

12.

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S . Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. PMC: 545600. DOI: 10.1186/gb-2004-5-10-r80. View

13.

Chen H, Chen G, Chen Y, Liao W, Liu C, Chang K . MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009; 100(6):1002-11. PMC: 2661776. DOI: 10.1038/sj.bjc.6604948. View

14.

Slattery M, Wolff R, Herrick J, Caan B, Potter J . IL6 genotypes and colon and rectal cancer. Cancer Causes Control. 2007; 18(10):1095-105. PMC: 2442470. DOI: 10.1007/s10552-007-9049-x. View

15.

He L, He X, Lim L, de Stanchina E, Xuan Z, Liang Y . A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447(7148):1130-4. PMC: 4590999. DOI: 10.1038/nature05939. View

16.

Alexander D, Cushing C . Red meat and colorectal cancer: a critical summary of prospective epidemiologic studies. Obes Rev. 2010; 12(5):e472-93. DOI: 10.1111/j.1467-789X.2010.00785.x. View

17.

Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

18.

Yang L, Belaguli N, Berger D . MicroRNA and colorectal cancer. World J Surg. 2009; 33(4):638-46. DOI: 10.1007/s00268-008-9865-5. View

19.

Aslam M, Taylor K, Pringle J, Jameson J . MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 2009; 96(7):702-10. DOI: 10.1002/bjs.6628. View

20.

Michael M, O Connor S, van Holst Pellekaan N, Young G, James R . Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1(12):882-91. View